52 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates http://www.zacks.com/stock/news/722255/pharma-stock-roundup-lly-dermira-buyout-offer-pipeline-regulatory-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-722255 Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction http://www.zacks.com/stock/news/722212/novo-nordisks-ozempic-gets-fda-nod-for-cv-risk-reduction?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-722212 Jan 17, 2020 - Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children http://www.zacks.com/stock/news/731608/jjs-stelara-gets-eu-nod-for-plaque-psoriasis-in-children?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-731608 Jan 24, 2020 - Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study http://www.zacks.com/stock/news/736760/aveo-posts-data-on-ficlatuzumab-from-pancreatic-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-736760 Jan 28, 2020 - AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More http://www.zacks.com/stock/news/738675/big-drug-biotech-stock-earnings-on-jan-30-biib-alxn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-738675 Jan 29, 2020 - Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review http://www.zacks.com/stock/news/738792/alkermes-alks-nda-for-alks-3831-accepted-by-fda-for-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-738792 Jan 29, 2020 - The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Eli Lilly & Co (LLY) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/01/30/eli-lilly-co-lly-q4-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Jan 30, 2020 - LLY earnings call for the period ending December 31, 2019.
Bayer Seeks FDA Approval for New Formulation of Nifurtimox http://www.zacks.com/stock/news/742609/bayer-seeks-fda-approval-for-new-formulation-of-nifurtimox?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-742609 Jan 31, 2020 - Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.
Eli Lilly Launches a New Migraine Drug https://www.fool.com/investing/2020/01/31/lilly-launches-a-new-migraine-drug.aspx?source=iedfolrf0000001 Jan 31, 2020 - Reyvow is the first drug in an entirely new class of acute migraine treatments.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative http://www.zacks.com/stock/news/742655/pharma-stock-roundup-lly-pfe-q4-results-jnjs-coronavirus-vaccine-initiative?cid=CS-ZC-FT-analyst_blog|stock_roundup-742655 Jan 31, 2020 - Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.

Pages: 123456

<Page 2>